[Ip-health] Senate tax bill will not make orphan drug tax credits transparent as to company, drug and disease | Knowledge Ecology International

James Love james.love at keionline.org
Sat Dec 2 05:51:17 PST 2017

In a reversal from the version that passed out of the Senate Finance
Committee, the version of the tax bill that passed the Senate eliminated
the requirement that the Orphan Drug tax credit be transparent as to
taxpayer, drug and indication, a victory for pharma, making R&D outlays and
public subsidies less transparent.

Lobbyists for drug companies were more focused on eliminating the
transparency provisions that preserving the higher rate of 50 percent. The
revised credit is 27.5 percent, which makes trials for orphan products 45
percent more expensive for a company financing a trial.


More information about the Ip-health mailing list